Citigroup Maintains Buy on Gracell Biotechnologies, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a 'Buy' rating on Gracell Biotechnologies (NASDAQ:GRCL), but lowered the price target from $12 to $11.
August 29, 2023 | 4:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup has maintained a 'Buy' rating on Gracell Biotechnologies but lowered the price target from $12 to $11.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the expected future value of the stock. However, the impact on the stock price in the short term is uncertain as the 'Buy' rating might still attract investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100